Prostaglandins regulate the synthesis and secretion of the atrial natriuretic peptide

David G. Gardner, Harold D Schultz

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

We have examined the effects of several PGs on the synthesis and release of the atrial natriuretic peptide (ANP) in vivo and in vitro. PGF infusion in anesthetized rats resulted in a significant increase in plasma immunoreactive (ir) ANP levels in vivo despite effecting only modest changes in hemodynamics. The PGs were also effective at promoting irANP secretion in primary cultures of neonatal rat atrial and ventricular cardiocytes. PGF increased irANP release with half-maximal induction seen at ∼ 10-8 M; PGE2 was somewhat less effective and prostacyclin (PGI2) was without effect. The PGs also increased ANP mRNA levels in these cells, suggesting that these agents exert a major effect on the synthesis as well as the secretion of the prohormone. Transient expression analysis of atrial cells transfected with 2,500 bp of human (h) ANP 5′ flanking sequence linked to a chloramphenicol acetyltransferase (CAT) reporter demonstrated that PGF (10-5 M) increased hANP promoter activity approximately twofold relative to the control. PGF had no effect on the promoterless control (pSV0-lamin CAT). Treatment of cultured atriocytes with high concentrations of a cyclooxygenase inhibitor resulted in a significant suppression of ANP secretion in vitro and a truncation of the plasma ANP response to volume infusion in vivo. Taken together these studies support a role for PGs as regulators of cardiac ANP synthesis and secretion, and suggest an additional mechanism whereby eicosanoids may act to control cardiovascular and renal homeostasis.

Original languageEnglish (US)
Pages (from-to)52-59
Number of pages8
JournalJournal of Clinical Investigation
Volume86
Issue number1
DOIs
StatePublished - Jan 1 1990

Fingerprint

Atrial Natriuretic Factor
Prostaglandins
Dinoprost
Chloramphenicol O-Acetyltransferase
Epoprostenol
Lamins
Cyclooxygenase Inhibitors
Eicosanoids
5' Flanking Region
Homeostasis
Hemodynamics
Kidney
Messenger RNA

Keywords

  • Atrial natriuretic peptide
  • Prostaglandins
  • Secretory control

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prostaglandins regulate the synthesis and secretion of the atrial natriuretic peptide. / Gardner, David G.; Schultz, Harold D.

In: Journal of Clinical Investigation, Vol. 86, No. 1, 01.01.1990, p. 52-59.

Research output: Contribution to journalArticle

@article{fc9d0e254f544eeba1ede10bf26e7005,
title = "Prostaglandins regulate the synthesis and secretion of the atrial natriuretic peptide",
abstract = "We have examined the effects of several PGs on the synthesis and release of the atrial natriuretic peptide (ANP) in vivo and in vitro. PGF2α infusion in anesthetized rats resulted in a significant increase in plasma immunoreactive (ir) ANP levels in vivo despite effecting only modest changes in hemodynamics. The PGs were also effective at promoting irANP secretion in primary cultures of neonatal rat atrial and ventricular cardiocytes. PGF2α increased irANP release with half-maximal induction seen at ∼ 10-8 M; PGE2 was somewhat less effective and prostacyclin (PGI2) was without effect. The PGs also increased ANP mRNA levels in these cells, suggesting that these agents exert a major effect on the synthesis as well as the secretion of the prohormone. Transient expression analysis of atrial cells transfected with 2,500 bp of human (h) ANP 5′ flanking sequence linked to a chloramphenicol acetyltransferase (CAT) reporter demonstrated that PGF2α (10-5 M) increased hANP promoter activity approximately twofold relative to the control. PGF2α had no effect on the promoterless control (pSV0-lamin CAT). Treatment of cultured atriocytes with high concentrations of a cyclooxygenase inhibitor resulted in a significant suppression of ANP secretion in vitro and a truncation of the plasma ANP response to volume infusion in vivo. Taken together these studies support a role for PGs as regulators of cardiac ANP synthesis and secretion, and suggest an additional mechanism whereby eicosanoids may act to control cardiovascular and renal homeostasis.",
keywords = "Atrial natriuretic peptide, Prostaglandins, Secretory control",
author = "Gardner, {David G.} and Schultz, {Harold D}",
year = "1990",
month = "1",
day = "1",
doi = "10.1172/JCI114714",
language = "English (US)",
volume = "86",
pages = "52--59",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "1",

}

TY - JOUR

T1 - Prostaglandins regulate the synthesis and secretion of the atrial natriuretic peptide

AU - Gardner, David G.

AU - Schultz, Harold D

PY - 1990/1/1

Y1 - 1990/1/1

N2 - We have examined the effects of several PGs on the synthesis and release of the atrial natriuretic peptide (ANP) in vivo and in vitro. PGF2α infusion in anesthetized rats resulted in a significant increase in plasma immunoreactive (ir) ANP levels in vivo despite effecting only modest changes in hemodynamics. The PGs were also effective at promoting irANP secretion in primary cultures of neonatal rat atrial and ventricular cardiocytes. PGF2α increased irANP release with half-maximal induction seen at ∼ 10-8 M; PGE2 was somewhat less effective and prostacyclin (PGI2) was without effect. The PGs also increased ANP mRNA levels in these cells, suggesting that these agents exert a major effect on the synthesis as well as the secretion of the prohormone. Transient expression analysis of atrial cells transfected with 2,500 bp of human (h) ANP 5′ flanking sequence linked to a chloramphenicol acetyltransferase (CAT) reporter demonstrated that PGF2α (10-5 M) increased hANP promoter activity approximately twofold relative to the control. PGF2α had no effect on the promoterless control (pSV0-lamin CAT). Treatment of cultured atriocytes with high concentrations of a cyclooxygenase inhibitor resulted in a significant suppression of ANP secretion in vitro and a truncation of the plasma ANP response to volume infusion in vivo. Taken together these studies support a role for PGs as regulators of cardiac ANP synthesis and secretion, and suggest an additional mechanism whereby eicosanoids may act to control cardiovascular and renal homeostasis.

AB - We have examined the effects of several PGs on the synthesis and release of the atrial natriuretic peptide (ANP) in vivo and in vitro. PGF2α infusion in anesthetized rats resulted in a significant increase in plasma immunoreactive (ir) ANP levels in vivo despite effecting only modest changes in hemodynamics. The PGs were also effective at promoting irANP secretion in primary cultures of neonatal rat atrial and ventricular cardiocytes. PGF2α increased irANP release with half-maximal induction seen at ∼ 10-8 M; PGE2 was somewhat less effective and prostacyclin (PGI2) was without effect. The PGs also increased ANP mRNA levels in these cells, suggesting that these agents exert a major effect on the synthesis as well as the secretion of the prohormone. Transient expression analysis of atrial cells transfected with 2,500 bp of human (h) ANP 5′ flanking sequence linked to a chloramphenicol acetyltransferase (CAT) reporter demonstrated that PGF2α (10-5 M) increased hANP promoter activity approximately twofold relative to the control. PGF2α had no effect on the promoterless control (pSV0-lamin CAT). Treatment of cultured atriocytes with high concentrations of a cyclooxygenase inhibitor resulted in a significant suppression of ANP secretion in vitro and a truncation of the plasma ANP response to volume infusion in vivo. Taken together these studies support a role for PGs as regulators of cardiac ANP synthesis and secretion, and suggest an additional mechanism whereby eicosanoids may act to control cardiovascular and renal homeostasis.

KW - Atrial natriuretic peptide

KW - Prostaglandins

KW - Secretory control

UR - http://www.scopus.com/inward/record.url?scp=0025358712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025358712&partnerID=8YFLogxK

U2 - 10.1172/JCI114714

DO - 10.1172/JCI114714

M3 - Article

VL - 86

SP - 52

EP - 59

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 1

ER -